Log in

NASDAQ:MTPMidatech Pharma Stock Price, Forecast & News

$1.38
-0.02 (-1.43 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.37
Now: $1.38
$1.44
50-Day Range
$1.25
MA: $1.41
$1.55
52-Week Range
$0.86
Now: $1.38
$13.60
Volume57,600 shs
Average Volume134,179 shs
Market Capitalization$9.00 million
P/E RatioN/A
Dividend YieldN/A
Beta2.71
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer. Midatech Pharma PLC is collaborating with universities and pharmaceutical companies to develop its platform technologies into a range of products. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.73 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MTP
CUSIPN/A
Phone44-12-3588-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$860,000.00
Book Value$40.82 per share

Profitability

Miscellaneous

Employees73
Market Cap$9.00 million
Next Earnings Date9/21/2020 (Estimated)
OptionableNot Optionable

Receive MTP News and Ratings via Email

Sign-up to receive the latest news and ratings for MTP and its competitors with MarketBeat's FREE daily newsletter.

Midatech Pharma (NASDAQ:MTP) Frequently Asked Questions

How has Midatech Pharma's stock been impacted by COVID-19 (Coronavirus)?

Midatech Pharma's stock was trading at $3.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MTP stock has decreased by 55.8% and is now trading at $1.38. View which stocks have been most impacted by Coronavirus.

When is Midatech Pharma's next earnings date?

Midatech Pharma is scheduled to release its next quarterly earnings announcement on Monday, September 21st 2020. View our earnings forecast for Midatech Pharma.

Has Midatech Pharma been receiving favorable news coverage?

News stories about MTP stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Midatech Pharma earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Midatech Pharma.

Who are some of Midatech Pharma's key competitors?

What other stocks do shareholders of Midatech Pharma own?

Who are Midatech Pharma's key executives?

Midatech Pharma's management team includes the following people:
  • Mr. Nicholas John Robbins-Cherry, CFO, Company Sec. & Director (Age 50)
  • Dr. Craig Richard Cook, CEO, COO & Director (Age 52)
  • Mr. Rob Rainey FCA MBA MA, Head of Corp. Devel.
  • Dr. Tim Sparey Ph.D., Chief Bus. Officer
  • Mr. Justin Barry BSc (Hons.), MBIOL, CBIOL, QP, Head of Manufacturing

What is Midatech Pharma's stock symbol?

Midatech Pharma trades on the NASDAQ under the ticker symbol "MTP."

How do I buy shares of Midatech Pharma?

Shares of MTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Midatech Pharma's stock price today?

One share of MTP stock can currently be purchased for approximately $1.38.

How big of a company is Midatech Pharma?

Midatech Pharma has a market capitalization of $9.00 million and generates $860,000.00 in revenue each year. Midatech Pharma employs 73 workers across the globe.

What is Midatech Pharma's official website?

The official website for Midatech Pharma is www.midatechpharma.com.

How can I contact Midatech Pharma?

Midatech Pharma's mailing address is ODDFELLOWS HOUSE 19 NEWPORT ROAD, CARDIFF X0, CF24 0AA. The company can be reached via phone at 44-12-3588-8300 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.